1. Conversion of MyoD to a neurogenic factor: binding site specificity determines lineage
- Author
-
Zizhen Yao, Gist H. Farr, Abraham P Fong, Lisa Maves, Nathan M. Johnson, Stephen J. Tapscott, and Jun Wen Zhong
- Subjects
animal structures ,Mutant ,Biology ,MyoD ,Muscle Development ,General Biochemistry, Genetics and Molecular Biology ,Article ,E-Box Elements ,03 medical and health sciences ,Mice ,0302 clinical medicine ,MyoD Protein ,Animals ,Amino Acid Sequence ,Binding site ,lcsh:QH301-705.5 ,Peptide sequence ,030304 developmental biology ,Genetics ,Neurons ,0303 health sciences ,Binding Sites ,Myogenesis ,Cell Differentiation ,musculoskeletal system ,lcsh:Biology (General) ,NEUROD2 ,tissues ,030217 neurology & neurosurgery - Abstract
SummaryMyoD and NeuroD2, master regulators of myogenesis and neurogenesis, bind to a “shared” E-box sequence (CAGCTG) and a “private” sequence (CAGGTG or CAGATG, respectively). To determine whether private-site recognition is sufficient to confer lineage specification, we generated a MyoD mutant with the DNA-binding specificity of NeuroD2. This chimeric mutant gained binding to NeuroD2 private sites but maintained binding to a subset of MyoD-specific sites, activating part of both the muscle and neuronal programs. Sequence analysis revealed an enrichment for PBX/MEIS motifs at the subset of MyoD-specific sites bound by the chimera, and point mutations that prevent MyoD interaction with PBX/MEIS converted the chimera to a pure neurogenic factor. Therefore, redirecting MyoD binding from MyoD private sites to NeuroD2 private sites, despite preserved binding to the MyoD/NeuroD2 shared sites, is sufficient to change MyoD from a master regulator of myogenesis to a master regulator of neurogenesis.
- Published
- 2015